Loading clinical trials...
Loading clinical trials...
LCCC 2044: Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
The primary goal of this study is to examine whether recurrence of HPV-associated OPSCC can be predicted by two factors: 1) mutations in genes called TRAF3 and CYLD, and 2) measurements of circulating HPV DNA in blood plasma. The study will also investigate whether HPV integration is associated with TRAF3 and CYLD mutations, and whether recurrence prediction improves when looking at HPV integration along with TRAF3 and CYLD mutations.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Mayo Clinic
Rochester, Minnesota, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Trident Medical Center (HCA Healthcare )
North Charleston, South Carolina, United States
Start Date
November 19, 2020
Primary Completion Date
November 1, 2033
Completion Date
November 1, 2033
Last Updated
April 27, 2025
220
ESTIMATED participants
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
NCT05039801
NCT06980038
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions